期刊文献+

RPL34基因在胃癌组织中的表达及其与临床病理特征的关系 被引量:1

Expression of RPL34 Gene in Gastric Cancer and Its Relationship with Clinicopathological Features
下载PDF
导出
摘要 目的探讨胃癌中核糖体蛋白L34(RPL34)基因的表达及其与胃癌发生、发展和胃癌患者临床病理特征的关系。方法收集2018年2月至2019年2月在无锡市第五人民医院治疗的60例胃癌患者的胃癌组织标本、配对癌旁组织(距肿瘤边缘≥3 cm)及正常胃黏膜组织,采用实时聚合酶链反应法检测不同胃癌细胞株RPL34基因信使RNA(mRNA)的表达水平;采用免疫组织化学法检测胃癌组织、配对癌旁组织及正常胃黏膜组织RPL34基因的表达情况,分析RPL34基因与胃癌患者临床病理特征的关系。结果不同胃癌细胞株中RPL34 mRNA的相对表达率比较差异有统计学意义(P<0.01),其中MGC80-3胃癌细胞株中RPL34 mRNA的表达最高。RPL34在胃癌组织、配对癌旁组织及正常胃黏膜组织中的表达率分别为81.7%(49/60)、38.3%(23/60)和10.0%(6/60),差异有统计学意义(P<0.01)。胃癌组织中RPL34蛋白的表达水平为0.634±0.003,高于正常胃黏膜组织的0.166±0.001(P<0.01)。不同肿瘤分化程度、淋巴结转移、TNM分期的RPL34基因阳性表达率比较差异有统计学意义(均P<0.01),病理分化程度越差、合并淋巴结转移且TNM分期越晚的胃癌患者RPL34基因阳性表达率越高。结论RPL34可能参与胃癌的发生、发展及侵袭转移过程,对胃癌的早期诊断及预后评估具有一定的指导意义,并可能成为胃癌治疗的新靶点。 Objective To investigate the expression of ribosomal protein L34(RPL34)gene in gastric cancer and to explore its relationship with genesis and progression and the clinicopathological features of gastric cancer.Methods Between Feb.2018 and Feb.2019,gastric cancer tissues,paired adjacent tissues(≥3 cm from the edge of the tumor)and gastric normal musoca tissues were collected from 60 patients who underwent treatment at the Department of General Surgery,Wuxi Second People’s Hospital.The expression levels of RPL34 mRNA in various gastric cancer cell lines were detected by real-time polymerase chain reaction,and the RPL34 gene expression in gastric cancer,paired adjacent tissue and gastric normal musoca tissue were detected by the immunohistochemistry method,and the relationship between the RPL34 gene expression and clinicopathological features was analyzed.Results There were significantly differences in the relative expression levels of RPL34 mRNA in different gastric cancer cell lines(P<0.01),among them,the expression of RPL34 gene in MGC80-3 was the highest.The expression rate of RPL34 in gastric cancer tissue,paired adjacent tissue and gastric normal musoca tissue were as follows:81.7%(49/60),38.3%(23/60)and 10.0%(6/60),the difference was statistically significant(P<0.01).The expression of RPL34 protein in gastric cancer tissue was 0.634±0.003,higher than that of gastric normal mucosa’s 0.166±0.001(P<0.01).There was a significant difference in the positive expression rate of RPL34 gene in tissues of different degrees of differention,lymph node metastasis an TNM stage(all P<0.01),the positive expression rate of RPL34 was higher in gastric cancer patients who were with lower pathological differentiation degree,with lymph node metastasis,and higher TNM stage.Conclusion RPL34 gene may be involved in the genesis,development,invasion and metastasis of gastric cancer,therefore is of great significance in the early diagnosis and prognosis assessment,and may also become a new target for the treatment.
作者 刘慧 张彬彬 王昊楠 曹斐 吴晓霞 单永锋 郁皓 LIU Hui;ZHANG Binbin;WANG Haonan;CAO Fei;WU Xiaoxia;SHAN Yongfeng;YU Hao(Department of Oncology,Wuxi Fifth People′s Hospital,Wuxi 214000,China)
出处 《医学综述》 2019年第21期4316-4320,共5页 Medical Recapitulate
基金 南京医科大学科技发展基金(NMUB2018279)
关键词 胃肿瘤 核糖体蛋白L34基因 免疫组织化学 实时聚合酶链反应 Stomach neoplasms Ribosomal proteins L34 gene Immunohistochemistry Real-time polymerase chain reaction
  • 相关文献

参考文献2

二级参考文献36

  • 1宋振川,李勇,焦志凯,赵群,焦锟,范立桥,刘羽,王爱军.胸苷磷酸化酶在胃癌及癌周组织中分布的研究[J].中华综合临床医学杂志(北京),2004,6(12):9-11. 被引量:9
  • 2钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 3李明毅,林大任,谭洁媚,刘秀娟.紫杉醇联合卡培他滨治疗晚期胃癌的初步报告[J].海南医学,2005,16(8):3-5. 被引量:5
  • 4盛建明,马志敏,赵文和,吴灵娇,胡中荣,陈瑜.胃癌中胸苷磷酸化酶和二氢嘧啶脱氢酶含量及其比值的测定[J].全科医学临床与教育,2006,4(5):376-378. 被引量:4
  • 5秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 6Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲ trial of capecitabine/cisplatin (XP) vs.continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):efficacy and safety results[J].Proc Am Soc Clin Oncol,2006,24:a LBA4018.
  • 7Lee SS,Lee JL,Ryu MH,et al.Combination chemotherapy with capecitabine (x) and cisplatin (p) as first line treatment in advanced gastric cancer:experience of 223 patients with prognostic factor analysis[J].Jpn J Clin Oncol,2007,37(1):30-37.
  • 8Petrovic Z,Tarabar D,Doder R,et al.Oxaliplatin (L-OHP) and capecitabine (X) as second line chemotherapy in patients with advanced gastric cancer[J].Proc Am Soc Clin Oncol,2003,22:a1199.
  • 9Park Y,Kim B,Ryoo B,et al.A phase Ⅱ study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer[J].Br J Cancer,2006,94(7):959-963.
  • 10Park Y,Lee J,Ryoo B,et al.A phase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer[J].J Clin Oncol,2006,24(18S):4079.

共引文献144

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部